Clarkston Capital Partners LLC Sells 235,144 Shares of Becton, Dickinson and Company $BDX

Clarkston Capital Partners LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 64.2% during the first quarter, HoldingsChannel.com reports. The firm owned 131,106 shares of the medical instruments supplier’s stock after selling 235,144 shares during the period. Becton, Dickinson and Company accounts for 1.6% of Clarkston Capital Partners LLC’s portfolio, making the stock its 23rd biggest position. Clarkston Capital Partners LLC’s holdings in Becton, Dickinson and Company were worth $20,614,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new position in Becton, Dickinson and Company in the third quarter valued at $25,000. Steph & Co. lifted its position in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares in the last quarter. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $26,000. Meeder Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the last quarter. Finally, Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

BDX has been the topic of several analyst reports. Piper Sandler dropped their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus decreased their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Barclays upped their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Evercore set a $180.00 price objective on Becton, Dickinson and Company in a report on Monday, July 6th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average target price of $180.29.

Becton, Dickinson and Company Stock Up 0.0%

Shares of BDX stock opened at $153.16 on Friday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The stock has a market cap of $42.20 billion, a price-to-earnings ratio of 38.78, a PEG ratio of 10.84 and a beta of 0.21. The firm’s 50-day moving average is $149.70 and its 200-day moving average is $165.03. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 5,188 shares of company stock worth $765,120. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.